Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer

Anticancer Res. 2017 Sep;37(9):4979-4986. doi: 10.21873/anticanres.11909.

Abstract

Background/aim: Pancreatobiliary cancer is a disease associated with a dismal prognosis and limited treatment options. The aim of the present study was to clarify the usefulness of circulating galectin-3 in pancreatobiliary cancer.

Patients and methods: We examined serum galectin-3 concentrations in 45 patients with pancreatobiliary cancer. Receiver operating characteristic curves were utilized to evaluate the accuracy of circulating galectin-3 to discriminate pancreatobiliary cancer patients from controls and predict the prognostic outcomes.

Results: Circulating galectin-3 had diagnostic value at the cut-off level of 6.2 ng/ml, and the patients' overall survival was predictable at the cut-off level of 10.3 ng/ml. Furthermore, circulating galectin-3 ≥10.3 ng/ml was an independent prognostic marker in pancreatobiliary cancer. Regarding biliary cancer, higher galectin-3 was associated with malnutrition. On the other hand, regarding pancreatic cancer, higher galectin-3 levels were associated with higher inflammatory parameters.

Conclusion: Galectin-3 can be a useful biomarker in patients with pancreatobiliary cancer.

Keywords: Galectin-3; intercellular adhesion molecule-1; interleukin-6; malnutrition.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biliary Tract Neoplasms / blood
  • Biliary Tract Neoplasms / mortality*
  • Biliary Tract Neoplasms / pathology
  • Biomarkers, Tumor / blood*
  • Case-Control Studies
  • Female
  • Follow-Up Studies
  • Galectin 3 / blood*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pancreatic Neoplasms / blood
  • Pancreatic Neoplasms / mortality*
  • Pancreatic Neoplasms / pathology
  • Prognosis
  • ROC Curve
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • Galectin 3